Prognostic factors in acute myeloid leukemia

Current Opinion in Hematology

Volumn 12, Issue 1, 2005, Pages 62-67

  Avivi, Irit ^a   Rowe, Jacob M ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Acute myeloid leukemia; Cytogenetics; FLT3; Gene expression profile; Prognosis

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; FLT3 LIGAND; MIXED LINEAGE LEUKEMIA PROTEIN; MOLECULAR MARKER; MULTIDRUG RESISTANCE PROTEIN; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CYTOGENETICS; DNA PROBE; FLOW CYTOMETRY; GENE CLUSTER; GENE EXPRESSION PROFILING; HUMAN; LONG TERM CARE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; RELAPSE; REVIEW; RISK FACTOR; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

CYTOGENETIC ANALYSIS; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; MUTATION; NEOPLASM, RESIDUAL; PROGNOSIS; PROTEOMICS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 13244288022     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moh.0000148760.15412.df     Document Type: Review

References (41)

1. Tallman MS, Kim HT, Paietta E, et al.: Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group. J Clin Oncol 2004, 22:1276-1286.
2. Haferlach T, Kern W, Schoch C, et al.: A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. Haematologica 2004, 89:408-418.
3. Rowe JM, Neuberg D, Friedenberg W, et al.: A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004, 103:479-485.
4. Grimwade D, Walker H, Harrison G, et al.: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
5. Kiyoi H, Naoe T, Nakano Y, et al.: Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999, 93:3074-3080.
6. Kottaridis PD, Gale RE, Frew ME, et al.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
7. Schnittger S, Schoch C, Dugas M, et al.: Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002, 100:59-66.
8. Yamamoto Y, Kiyoi H, Nakano Y, et al.: Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97:2434-2439.
9. Shih LY, Kuo MC, Liang DC, et al.: Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer 2003, 98:1206-1216.
10. Au WY, Fung A, Chim CS, et al.: FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact. Br J Haematol 2004, 125:463-469.
11. Ozeki K, Kiyoi H, Hirose Y, et al.: Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004, 103:1901-1908.
12. Dohner K, Tobis K, Ulrich R, et al.: Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002, 20:3254-3261.
13. Steudel C, Wermke M, Schaich M, et al.: Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer 2003, 37:237-251.
14. Frohling S, Schlenk RF, Stolze I, et al.: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004, 22:624-633.
15. Barragan E, Cervera J, Bolufer P, et al.: Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004, 89:926-933.
16. Ogawa H, Tamaki H, Ikegame K, et al.: The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003, 101:1698-1704.
17. Galimberti S, Testi R, Guerrini F, et al.: The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia. J Chemother 2003, 15:374-379.
18. Tan Y, Li G, Zhao C, et al.: Expression of sorcin predicts poor outcome in acute myeloid leukemia. Leuk Res 2003, 27:125-131.
19. Schaich M, Koch R, Soucek S, et al.: A sensitive model for prediction of relapse in adult acute myeloid leukaemia with t(8;21) using white blood cell count, CD56 and MDR1 gene expression at diagnosis. Br J Haematol 2004, 125:477-479.
20. Valk PJ, Verhaak RG, Beijen MA, et al.: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617-1628. This study is a major breakthrough in understanding the biology of AML. The use of gene expression profiling may improve the molecular classification of adult AML and affect treatment strategies and patient outcomes.
21. Bullinger L, Dohner K, Bair E, et al.: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004, 350:1605-1616. This very well designed study is a major breakthrough in understanding the biology of AML. The use of gene expression profiling may improve the molecular classification of adult AML and affect treatment strategies and patient outcomes.
22. Goldstone AH, Burnett AK, Avivi I, et al.: Secondary acute myeloid leukaemia always predicts worse outcome than de novo AML, regardless of cytogenetics or age. AML 10,11,12 MRC trials. Blood 2002, 100:322a.
23. Schoch C, Kern W, Schnittger S, et al.: Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004, 18:120-125. Patients with treatment-related AML were traditionally considered to have a poor prognosis. This study emphasizes the fact that cytogenetics still have a major prognostic impact on this population of patients.
24. Wheatley K, Burnett AK, Goldstone AH, et al.: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999, 107:69-79.
25. Estey EH, Shen Y, Thall PF, et al.: Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood 2000, 95:72-77.
26. Kern W, Haferlach T, Schoch C, et al.: Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003, 101:64-70. This study emphasizes the potential significance of rate of reduction in number of blasts for long-term outcome, similarly to the already established data for acute lymphoblastic leukemia, but not yet for AML.
27. Rowe JM, Kim HT, Cassileth PA, et al.: Time to complete remission is not a significant prognostic factor in AML: a report on 1,959 consecutive patients registered to 6 studies of the Eastern Cooperative Oncology Group (ECOG). ASH 2004. Blood 2004, 104:862a.
28. Raanani P, Ben-Bassat I: Detection of minimal residual disease in acute myelogenous leukemia. Acta Haematol 2004, 112:40-54.
29. Vidriales MB, San-Miguel JF, Orfao A, et al.: Minimal residual disease monitoring by flow cytometry. Baillieres Best Pract Res Clin Haematol 2003, 16:599-612.
30. Schmidt HH, Strehl S, Thaler D, et al.: RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications. Leukemia 2004, 18:1115-1121.
31. Varella-Garcia M, Hogan CJ, Odom LF, et al.: Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting. Leukemia 2001, 15:1408-1414.
32. Kottaridis PD, Gale RE, Linch DC: Flt3 mutations and leukaemia. Br J Haematol 2003, 122:523-538.
33. Ostergaard M, Olesen LH, Hasle H, et al.: WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients: results from a single-centre study. Br J Haematol 2004, 125:590-600.
34. San Miguel JF, Vidriales MB, Lopez-Berges C, et al.: Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001, 98:1746-1751.
35. Venditti A, Buccisano F, Del Poeta G, et al.: Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000, 96:3948-3952.
36. Keating S, Suciu S, de Witte T, et al.: The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia 2003, 17:60-67.
37. Fung HC, Stein A, Slovak M, et al.: A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003, 9:766-771.
38. Weltermann A, Fonatsch C, Haas OA, et al.: Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia 2004, 18:293-302. There are very scanty good data on prognostic factors at relapse. This study has successfully looked at this issue, emphasizing the independent significance of both remission duration and cytogenetics at relapse.
39. Tiesmeier J, Muller-Tidow C, Westermann A, et al.: Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy. Leuk Res 2004, 28:1069-1074.
40. Schlenk RF, Benner A, Krauter J, et al.: Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004, 22:3741-3750. This well-done study emphasizes the already known prognostic value of cytogenetics and indicates that (8;21), despite being considered as a favorable karyotype, has a significantly worse outcome at relapse, compared with inv [16].
41. Appelbaum FR, Rowe JM, Radich J, Dick JE: Acute myeloid leukemia. Hematology (American Society Hematology Education Program). 2001:62-86.